Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals i ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

On the Call Her Daddy podcast, American actress and stand-up comedian Amy Schumer, 43, discussed how online abuse from trolls ...

A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled “Pomalidomide improved immune profiles in myeloma." ...

BMO Capital analyst Kostas Biliouris has maintained their bullish stance on LEGN stock, giving a Buy rating yesterday.Invest with Confidence: ...

Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...

Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

Sanofi announces new Sarclisa subcutaneous formulation meets co-primary endpoints in IRAKLIA phase 3 study in multiple myeloma: Paris Friday, January 10, 2025, 15:00 Hrs [IST] Res ...

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma. Sarclisa SC formulation added to Pd for the treatment of R/R MM me ...